Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.
How can MRD and disease be assessed in routine practice?
Targeted therapies for CLL: new data and unanswered questions
Treating acute myeloid leukemia with VALOR – vosaroxin in combination with cytarabine
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients